Dr. Stephanie Lee and her staff are located at Fred Hutchinson Cancer Research Center. Our work focuses on hematopoietic stem cell transplant patients and chronic graft-versus-host disease (cGHVD). Dr. Lee is the lead investigator and Fred Hutchinson Cancer Research Center is the coordinating center for the Chronic Graft-versus-Host Disease Consortium within the Rare Diseases Clinical Research Network.This is funded by the Office of Rare Diseases Research (ORDR) within the National Center for Advancing Translational Sciences (NCATS).
Survivors of HCT experience may have higher complications, worse quality of life, and a shortened lifespan compared to people who do not undergo HCT. In people who receive stem cells from another person, unique immune mediated disorders such as cGVHD take a particularly high toll. Although components of these disorders resemble known autoimmune syndromes or solid organ allograft rejections, the underlying biology is poorly characterized. Dr. Lee’s research program is devoted to understanding late effects and cGVHD, and developing better approaches to the prevention, diagnosis and treatment of these treatment-related problems.
Dr. Lee's research emphasizes survivorship challenges, quality-of-life issues, and the impact of GVHD. Another area of interest is health-services research, which includes analysis of physician practices, doctor-patient communication, cost-effectiveness analysis, and similar policy issues.
In addition to her research projects, Dr. Lee is also the Research Director of the Long-Term-Follow-Up Program (LTFU) at Fred Hutchinson Cancer Research Center. This program follows more than 5,000 HCT survivors.